A weak heart makes a suffering brain
Heart problems cause disturbed gene activity in the brain’s memory center, from which cognitive deficits arise.
Heart problems cause disturbed gene activity in the brain’s memory center, from which cognitive deficits arise.
BeiGene, Ltd. a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of… read more.
PHOENIX, Arizona, February 26, 2021- Promising new research shows aerobic exercise may help slow memory loss for older adults living with Alzheimer’s dementia.
Tricida, Inc. provided an update on its FDA interactions. Tricida has received an Appeal Denied Letter (ADL), from the Office of New Drugs (OND) of the FDA in… read more.
Interview and article by Christine Clark Dr Mark Tomlin, consultant critical care pharmacist, describes how recent trial findings have identified effective treatments for the systemic inflammatory response syndrome… read more.
MISSOULA – University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting… read more.
Pfizer announced that the FDA accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE… read more.
New research from Baylor College of Medicine scientists shows that a combination of deep brain stimulation (DBS) and exercise has potential benefits for treating ataxia, a rare genetic… read more.
Interview and article by Christine Clark Although SARS-CoV-2 causes a mild illness in many people, some experience severe illness characterised by a systemic inflammatory response that can lead… read more.
Amgen announced the submission of a supplemental New Drug Application (sNDA) to the FDA for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are… read more.
Pfizer Inc.and BioNTech SE announced they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the… read more.
AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was… read more.